KR101172170B1 - 카파 선택적 오피오이드 수용체 길항제 - Google Patents

카파 선택적 오피오이드 수용체 길항제 Download PDF

Info

Publication number
KR101172170B1
KR101172170B1 KR1020107016401A KR20107016401A KR101172170B1 KR 101172170 B1 KR101172170 B1 KR 101172170B1 KR 1020107016401 A KR1020107016401 A KR 1020107016401A KR 20107016401 A KR20107016401 A KR 20107016401A KR 101172170 B1 KR101172170 B1 KR 101172170B1
Authority
KR
South Korea
Prior art keywords
disorder
pharmaceutically acceptable
ethanol
acceptable salt
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107016401A
Other languages
English (en)
Korean (ko)
Other versions
KR20100095639A (ko
Inventor
누리아 디아즈 부에조
데이비드 리 맥킨지
찰스 호워드 밋치
콘셉시온 페드레갈-테르세로
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20100095639A publication Critical patent/KR20100095639A/ko
Application granted granted Critical
Publication of KR101172170B1 publication Critical patent/KR101172170B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020107016401A 2008-01-22 2009-01-13 카파 선택적 오피오이드 수용체 길항제 Active KR101172170B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
EP08380012.8 2008-01-22
US3912108P 2008-03-25 2008-03-25
US61/039,121 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (2)

Publication Number Publication Date
KR20100095639A KR20100095639A (ko) 2010-08-31
KR101172170B1 true KR101172170B1 (ko) 2012-08-07

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107016401A Active KR101172170B1 (ko) 2008-01-22 2009-01-13 카파 선택적 오피오이드 수용체 길항제

Country Status (32)

Country Link
US (2) US7709522B2 (enExample)
EP (1) EP2252581B1 (enExample)
JP (1) JP5345637B2 (enExample)
KR (1) KR101172170B1 (enExample)
CN (1) CN101925576B (enExample)
AR (1) AR070158A1 (enExample)
AU (1) AU2009206653B2 (enExample)
BR (1) BRPI0907382B8 (enExample)
CA (1) CA2713025C (enExample)
CO (1) CO6290644A2 (enExample)
CY (1) CY1113071T1 (enExample)
DK (1) DK2252581T3 (enExample)
DO (1) DOP2010000222A (enExample)
EA (1) EA017484B1 (enExample)
EC (1) ECSP10010365A (enExample)
ES (1) ES2388708T3 (enExample)
HR (1) HRP20120558T1 (enExample)
IL (1) IL206038A (enExample)
JO (1) JO2797B1 (enExample)
MA (1) MA32751B1 (enExample)
MX (1) MX2010007849A (enExample)
MY (1) MY163014A (enExample)
NZ (1) NZ586225A (enExample)
PE (1) PE20091317A1 (enExample)
PL (1) PL2252581T3 (enExample)
PT (1) PT2252581E (enExample)
SI (1) SI2252581T1 (enExample)
TN (1) TN2010000306A1 (enExample)
TW (1) TWI422369B (enExample)
UA (1) UA100715C2 (enExample)
WO (1) WO2009094260A1 (enExample)
ZA (1) ZA201003908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2240485B1 (en) * 2008-01-22 2014-10-15 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
WO2013086496A2 (en) 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
ES2770978T3 (es) * 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
DK3596069T3 (da) 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
CN117615757A (zh) * 2021-05-04 2024-02-27 杨森制药公司 用于治疗抑郁症的组合物和方法
WO2022234457A1 (en) 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023131920A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2025503649A (ja) * 2022-01-10 2025-02-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のための組成物及び方法
CA3254546A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
EP4489748A1 (en) * 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026305A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) * 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
US20020052365A1 (en) * 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
WO2003082832A2 (en) * 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
EP1606275B1 (en) 2003-03-07 2008-08-27 Eli Lilly And Company Opioid receptor antagonists
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CN1890208A (zh) 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
BRPI0417714A (pt) 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2007528898A (ja) 2004-03-12 2007-10-18 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
MX2009002527A (es) 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026305A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist

Also Published As

Publication number Publication date
TWI422369B (zh) 2014-01-11
CA2713025C (en) 2012-12-04
DOP2010000222A (es) 2015-11-15
EP2252581A1 (en) 2010-11-24
DK2252581T3 (da) 2012-07-16
SI2252581T1 (sl) 2012-09-28
KR20100095639A (ko) 2010-08-31
IL206038A0 (en) 2010-11-30
BRPI0907382B1 (pt) 2020-03-10
EA017484B1 (ru) 2012-12-28
NZ586225A (en) 2012-05-25
CY1113071T1 (el) 2016-04-13
PL2252581T3 (pl) 2012-10-31
CO6290644A2 (es) 2011-06-20
US20100197669A1 (en) 2010-08-05
IL206038A (en) 2013-11-28
BRPI0907382A2 (pt) 2015-07-21
CN101925576A (zh) 2010-12-22
JO2797B1 (en) 2014-03-15
WO2009094260A1 (en) 2009-07-30
MY163014A (en) 2017-07-31
MA32751B1 (fr) 2011-11-01
TW200936129A (en) 2009-09-01
CA2713025A1 (en) 2009-07-30
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
ZA201003908B (en) 2011-11-30
JP2011524850A (ja) 2011-09-08
BRPI0907382B8 (pt) 2021-05-25
HRP20120558T1 (hr) 2012-10-31
UA100715C2 (ru) 2013-01-25
AR070158A1 (es) 2010-03-17
AU2009206653A1 (en) 2009-07-30
US7709522B2 (en) 2010-05-04
AU2009206653B2 (en) 2013-07-18
PT2252581E (pt) 2012-08-31
TN2010000306A1 (en) 2011-11-11
HK1146822A1 (en) 2011-07-15
ES2388708T3 (es) 2012-10-17
US8173695B2 (en) 2012-05-08
EA201070877A1 (ru) 2010-12-30
MX2010007849A (es) 2010-08-09
JP5345637B2 (ja) 2013-11-20
EP2252581B1 (en) 2012-06-20
PE20091317A1 (es) 2009-09-03
US20090186873A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
KR20100095639A (ko) 카파 선택적 오피오이드 수용체 길항제
KR102537686B1 (ko) D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도
WO2011075596A1 (en) Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8754132B2 (en) Highly selective 5-HT(2C) receptor agonists that show anti-psychotic effects with antagonist activity at the 5-HT(2B) receptor
ES2889876T3 (es) Ciclopropilmetanaminas como agonistas selectivos del receptor 5-HT(2C)
JP2011512414A (ja) 疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体
US20110136843A1 (en) Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
JP2011512414A5 (enExample)
HK1146822B (en) Kappa selective opioid receptor antagonist
KR20190104195A (ko) 치환된 3-디알킬아미노메틸-피페리딘-4-일-벤즈아미드 및 이를 제조 및 사용하는 방법
RS108904A (sr) N,n-disupstituisani diazocikloalkani korisni za tretman poremećaja cns usled serotonergijske disfunkcije
Paliwal et al. Discovery of a novel, potent and orally active series of γ-lactams as selective NK1 antagonists
US10377763B2 (en) Morphinan derivative and medical usage thereof
JP2014528416A (ja) ３−［２−メタンスルホニル−１−（４−トリフルオロメチル−フェノキシ）エチル］−ピロリジン化合物の結晶形態
HK40042967B (en) Use of known compounds as d-amino acid oxidase inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150630

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160721

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20170724

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20180718

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20190718

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 14